LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Pulmonx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.75−0.03 (-1.69%)
Close on Oct 19, 2026
- Market cap
- $74.32M
- P/E (TTM)
- –
- Dividend yield
- –
Pulmonx Corp revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $57.02M | $56.47M | $45.92M | $32.49M | $24.99M | $16.19M | $10.70M | $563.00K | 63.0% | +1.0% |
| EMEA | $26.99M | $22.33M | $19.34M | $18.15M | $19.88M | $13.81M | $18.36M | $16.18M | 29.8% | +20.9% |
| Asia Pacific | $6.23M | $4.44M | $3.02M | $2.87M | $3.41M | $2.69M | $3.23M | $3.12M | 6.9% | +40.3% |
| Other International | $260.00K | $556.00K | $399.00K | $155.00K | $128.00K | $49.00K | $300.00K | $151.00K | 0.3% | -53.2% |
From the segment and revenue-disaggregation notes of Pulmonx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.